Antihypertensive and renal effects of tertatolol, a new beta-blocking agent, in hypertensive patients

A. Salvetti, G. Leonetti, G. P. Bernini, L. Rupoli, [No Value] A.R.Lucarini, P. Sangiorgio, M. Mauro, P. Di Stratis, A. Zanchetti

Research output: Contribution to journalArticlepeer-review


Tertatolol, a new nonselective β-adrenoceptor blocker, was administered to 11 hypertensive patients in a short-term study. Systolic and diastolic blood pressure and heart rate were significantly decreased when compared to the placebo period: In spite of that glomerular filtration rate and renal plasma flow were unchanged. The administration of metoclopramide (a dopaminergic receptor antagonist) caused a significant reduction of renal plasma flow and a significant rise of renal vascular resistances during placebo, but no change during tertatolol therapy. A possible interference of tertatolol on dopaminergic receptors is discussed as the mechanism reponsible for the unmodified renal plasma flow despite the significant blood pressure lowering with tertatolol.

Original languageEnglish
Pages (from-to)45-49
Number of pages5
JournalAmerican Journal of Nephrology
Publication statusPublished - 1986


  • Dopaminergic receptors
  • Hypertension
  • Metoclopramide
  • Renal effects
  • Tertatolol
  • β-Adrenergic receptors

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Antihypertensive and renal effects of tertatolol, a new beta-blocking agent, in hypertensive patients'. Together they form a unique fingerprint.

Cite this